AbbVie Announces Next-Generation Immunology Drug Clinical Results and Portfolio Strengthening
ABBV Abbvie Inc
$285.19 +0.14%
View chart & analysis → - 1AbbVie recorded a 26% increase in its stock price this year based on strong financial performance.
- 2AbbVie's Skyrizi achieved approximately $10 billion in sales in the first half of this year.
- 3AbbVie acquired Apogee Therapeutics for $10.9 billion in cash earlier this year.
So what's the key point?
AbbVie spent a large amount of money to buy a company that makes new medicines. This company is making a lot of money by selling its drugs well.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.